Ovarian cancer: Diagnostic, biological and prognostic aspects

Women's Health

Volumn 10, Issue 5, 2014, Pages 519-533

  Davidson, Ben ^a,b   Tropé, Claes G ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

chemotherapy resistance; microenvironment; ovarian cancer; prognosis; progression

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; DICKKOPF 1 PROTEIN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIBROBLAST GROWTH FACTOR; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR GLI1; Y BOX BINDING PROTEIN 1; ANTINEOPLASTIC AGENT;

ARID1A GENE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; ERCC1 GENE; EXOSOME; GENE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; METASTASIS; MOLECULAR DIAGNOSIS; OVARY CANCER; REVIEW; STROMA; TUMOR SUPPRESSOR GENE; DISEASE COURSE; DRUG RESISTANCE; FEMALE; MOLECULARLY TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; WOMEN'S HEALTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; WOMEN'S HEALTH;

EID: 84908143088     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.37     Document Type: Review

References (122)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012
2. Davidson B. Ovarian and primary peritoneal carcinoma. In: Serous Effusions-Etiology, Diagnosis, Prognosis and Therapy. Davidson B, Firat P, Michael CW (Eds). Springer, London, UK, 47-68, 167-204 (2011
3. Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. doi: 10.1007/s10555-013-9456-9452 (2013) (Epub ahead of print
4. Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective. Acta Scand. Obstet. Gynecol. 91(3), 308-317 (2012
5. Berek JS, Bast RC Jr. Ovarian cancer. In: Cancer Medicine (7th Edition). Kufe DW, Bast RC Jr, Hait WM, et al. (Eds). BC Decker Inc., Hamilton, Canada, 1543-1568 (2006
6. Weissman SM, Weiss SM, Newlin AC. Genetic testing by cancer site: ovary. Cancer J. 18(4), 320-327 (2012
7. Caburet S, Georges A, L'Hôte D, Todeschini AL, Benayoun BA, Veitia RA. The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology. Mol. Cell. Endocrinol. 356(1-2), 55-64 (2012
8. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N. Engl. J. Med. 366(3), 234-242 (2012
9. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 460(3), 237-249 (2012
10. Gilks CB, Ionescu DN, Kalloger SE, et al. Cheryl Brown ovarian cancer outcomes unit of the british columbia cancer agency. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum. Pathol. 39(8), 1239-1251 (2008
11. Köbel M, Kalloger SE, Lee S, et al; Ovarian Tumor Tissue Analysis Consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol. Biomarkers Prev. 22(10), 1677-1686 (2013
12. Köbel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 64(7), 1004-1013 (2014
13. Ordóñez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv. Anat. Pathol. 19(3), 140-151 (2012
14. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 27(2), 161-174 (2008
15. Bárcena C, Oliva E. WT1 expression in the female genital tract. Adv. Anat. Pathol. 18(6), 454-465 (2011
16. McCluggage WG. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. J. Clin. Pathol. 65(7), 596-600 (2012
17. Nik NN, Vang R, Shih IeM, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu. Rev. Pathol. 9, 27-45 (2014
18. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic highgrade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol. 226(3), 421-426 (2012
19. Tropé CG, Davidson B, Dørum A, et al. Epithelial ovarian cancer. In: Gynecologic Oncology. Trope CG, Peltecu GC (Eds). Editura Academiei Romane, Bucharest, Romania, 357-444 (2010
20. Delair D, Soslow RA. Key features of extrauterine pelvic serous tumours (Fallopian tube, ovary, and peritoneum). Histopathology 61(3), 329-339 (2012
21. Leen SL, Singh N. Pathology of primary and metastatic mucinous ovarian neoplasms. J. Clin. Pathol. 65(7), 591-595 (2012
22. Zaid TM, Yeung TL, Thompson MS, et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin. Cancer Res. 19(4), 809-820 (2013
23. Marmé F, Hielscher T, Hug S, et al. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int. J. Cancer 131(4), e586-e591 (2012
24. de Graeff P, Crijns AP, Ten Hoor KA, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br. J. Cancer 99(2), 341-349 (2008
25. Tanabe H, Nishii H, Sakata A, et al. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol. Oncol. 94(3), 735-739 (2004
26. Abe A, Minaguchi T, Ochi H, et al. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. Hum. Pathol. 44(2), 199-207 (2013
27. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 460(1), 77-87 (2012
28. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod. Pathol. 24(8), 1146-1155 (2011
29. Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin. Exp. Metastasis. 28(6), 581-591 (2011
30. Gan A, Green AR, Nolan CC, Martin S, Deen S. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum. Pathol. 44(8), 1638-1647 (2013
31. Banerjee S, Kaye SB. New Strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin. Cancer Res. 19(5), 961-968 (2013
32. O'Brien PM, Davies MJ, Scurry JP, et al. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br. J. Cancer 98(6), 1085-1093 (2008
33. Weberpals JI, Tu D, Squire JA, et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann. Oncol. 22(11), 2403-2410 (2011
34. Carser JE, Quinn JE, Michie CO, et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol. Oncol. 123(3), 492-498, (2011
35. Rubatt JM, Darcy KM, Tian C, et al. Pre-Treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol. Oncol. 125(2), 421-426 (2012
36. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221(1), 49-56 (2010
37. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progressionfree survival and chemoresistance in ovarian clear cell carcinoma. Mod. Pathol. 25(2), 282-288 (2012
38. Rahman MT, Nakayama K, Rahman M, et al. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 118(11), 2846-2857 (2012
39. Palmieri C, Gojis O, Rudraraju B, et al. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br. J. Cancer 108(10), 2039-2044 (2013
40. Mhawech-Fauceglia P, Wang D, Samrao D, et al. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Gynecol. Oncol. 127(1), 198-201 (2012
41. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-Analysis. Gynecol. Oncol. 124(2), 192-198 (2012
42. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22(3), 393-402 (2009
43. Milne K, Köbel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 4(7), e6412 (2009
44. Tsofack SP, Meunier L, Sanchez L, et al. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis. BMC Cancer 13, 303 (2013
45. Li C, Li Y, Wang X, et al. Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma. Histopathology 60(6), 953-963 (2012
46. Min KW, Park MH, Hong SR, et al.; Gynecologic Pathology Study Group of the Korean Society of Pathologists. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int. J. Gynecol. Pathol. 32(1), 3-14 (2013
47. Yang F, Guo X, Yang G, Rosen DG, Liu J. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Mod. Pathol. 24(6), 836-845 (2011
48. Köbel M, Xu H, Bourne PA, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod. Pathol. 22(3), 469-475 (2009
49. Spowart JE, Townsend KN, Huwait H, et al. The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. J. Pathol. 228(4), 437-447 (2012
50. Sieh W, Köbel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis Consortium study. Lancet Oncol. 14(9), 853-862 (2013
51. Aust S, Bachmayr-Heyda A, Pateisky P, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer-study of the OVCAD Consortium. Mol. Cancer 11, 69 (2012
52. Leffers N, Gooden MJ, Mokhova AA, et al. Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol. Oncol. 113(2), 256-263 (2009
53. Tothill RW, Tinker AV, George J, et al. Australian Ovarian Cancer Study Group. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14(16), 5198-5208 (2008
54. Sfakianos GP, Iversen ES, Whitaker R, et al. Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol. Oncol. 129(1), 159-164 (2013
55. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011
56. Kang J, D'Andrea AD, Kozono D. A DNA repair pathwayfocused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J. Natl Cancer Inst. 104(9), 670-681 (2012
57. Verhaak RG, Tamayo P, Yang JY, et al. Cancer Genome Atlas Research Network. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123(1), 517-525 (2013
58. Konstantinopoulos PA, Cannistra SA, Fountzilas H, et al. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS ONE 6(3), e18202 (2011
59. Sabatier R, Finetti P, Bonensea J, et al. A seven-gene prognostic model for platinum-Treated ovarian carcinomas. Br. J. Cancer 105(2), 304-311 (2011
60. Trinh XB, Tjalma WA, Dirix LY, et al. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS ONE 6(7), e22469 (2011
61. Schwede M, Spentzos D, Bentink S, et al. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS ONE 8(3), e57799 (2013
62. Tan DS, Iravani M, McCluggage WG, et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin. Cancer Res. 17(6), 1521-1534 (2011
63. Tan TZ, Miow QH, Huang RY, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol. Med. 5(7), 983-998 (2013
64. White KL, Vierkant RA, Fogarty ZC, et al. Analysis of over 10, 000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. Cancer Epidemiol. Biomarkers Prev. 22(5), 987-992 (2013
65. Bearfoot JL, Choong DY, Gorringe KL, Campbell IG. Genetic analysis of cancer-implicated microRNA in ovarian cancer. Clin. Cancer Res. 14(22), 7246-7250 (2008
66. Ryland GL, Bearfoot JL, Doyle MA, et al. MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS ONE 7(4), e35805 (2012
67. Permuth-Wey J, Chen Z, Tsai YY, et al. Ovarian Cancer Association Consortium (OCAC). MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomarkers Prev. 20(8), 1793-1797 (2011
68. Polytarchou C, Iliopoulos D, Hatziapostolou M, et al. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res. 71(13), 4720-4731 (2011
69. Corney DC, Hwang CI, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16(4), 1119-1128 (2010
70. Yeh YM, Chuang CM, Chao KC, Wang LH. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1. Int. J. Cancer 133(4), 867-878 (2013
71. Liu Z, Liu J, Segura MF, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J. Pathol. 228(2), 204-215 (2012
72. Bendoraite A, Knouf EC, Garg KS, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-Toepithelial transition. Gynecol. Oncol. 116(1), 117-125 (2010
73. Sun C, Li N, Yang Z, et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J. Natl Cancer Inst. 105(22), 1750-1758 (2013
74. Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2, e40 (2013
75. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 586(9), 1279-1286 (2012
76. Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc. Natl Acad. Sci. USA 110(24), 9845-9850 (2013
77. Boyerinas B, Park SM, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian cancer to taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int. J. Cancer 130(8), 1787-1797 (2012
78. Laios A, O'Toole S, Flavin R, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer 7, 35 (2008
79. Vang S, Wu HT, Fischer A, et al. Identification of ovarian cancer metastatic miRNAs. PLoS ONE 8(3), e58226 (2013
80. Vaksman O, Tuft Stavnes H, Kærn J, Trope CG, Davidson B, Reich R. miRNA profiling along tumor progression in ovarian carcinoma. J. Cell Mol. Med. 15(7), 1593-1602 (2011
81. Flavin R, Smyth P, Barrett C, et al. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int. J. Gynecol. Cancer 19(4), 641-647 (2009
82. Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol. Rep. 27(4), 1238-1244 (2012
83. Chao A, Lin CY, Lee YS, et al Regulation of ovarian cancer progression by microRNA-187 through targeting disabled homolog-2. Oncogene 31(6), 764-775 (2012
84. Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol. Oncol. 114(3), 457-464 (2009
85. Marchini S, Cavalieri D, Fruscio R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 12(3), 273-285 (2011
86. Wang S, Zhao X, Wang J, et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med. Oncol. 30(3), 681 (2013
87. Wurz K, Garcia RL, Goff BA, et al. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 49(7), 577-584 (2010
88. Shih KK, Qin LX, Tanner EJ, et al. A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol. Oncol. 121(3), 444-450 (2011
89. Tang Z, Ow GS, Thiery JP, Ivshina AV, Kuznetsov VA. Meta-Analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int. J. Cancer 134(2), 306-318 (2014
90. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-Associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol. Cancer Res. 10(11), 1403-1418 (2012
91. Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 1832(7), 1070-1078 (2013
92. Polanska UM, Orimo A. Carcinoma-Associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J. Cell Physiol. 228(8), 1651-1657 (2013
93. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 73(16), 4965-4977 (2013
94. Qiu W, Hu M, Sridhar A, et al. No evidence of clonal somatic genetic alterations in cancer-Associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 40(5), 650-655 (2008
95. Kataoka F, Tsuda H, Arao T, et al. EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy. Genes Chromosomes Cancer 51(3), 300-312 (2012
96. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007
97. Beach A, Zhang HG, Ratajczak MZ, Kakar SS. Exosomes: an overview of biogenesis, composition and role in ovarian cancer. J. Ovarian Res. 7(1), 14 (2014
98. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 9, 244 (2009
99. English DP, Santin AD. Claudins overexpression in ovarian cancer: potential targets for Clostridium perfringens enterotoxin (CPE) based diagnosis and therapy. Int. J. Mol. Sci. 14(5), 10412-10437 (2013
100. Escrevente C, Grammel N, Kandzia S, et al. Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells. PLoS ONE 8(10), e78631 (2013
101. Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-Tumor immunity. Oncol. Rep. 25(3), 749-762 (2011
102. Liang B, Peng P, Chen S, et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J. Proteomics 80C, 171-182 (2013
103. Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD, Rice GE. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J. Transl. Med. 12, 4 (2014
104. Cho JA, Park H, Lim EH, et al. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123(2), 379-386 (2011
105. McCann CK, Growdon WB, Kulkarni-Datar K, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS ONE 6(11), e28077 (2011
106. Mitra AK, Zillhardt M, Hua Y, et al. MicroRNAs reprogram normal fibroblasts into cancer-Associated fibroblasts in ovarian cancer. Cancer Discov. 2(12), 1100-1108 (2012
107. Kleinberg L, Dong HP, Holth A, et al. Cleaved caspases and NF-κB p65 are prognostic factors in metastatic ovarian carcinoma. Hum. Pathol. 40(6), 795-806 (2009
108. Stavnes HT, Holth A, Don T, et al. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecol. Oncol. 129(2), 358-363 (2013
109. Hetland TE, Hellesylt E, Flørenes VA, Tropé CG, Davidson B, Kærn J. Class III beta-Tubulin expression in advancedstage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum. Pathol. 42(7), 1019-1026 (2011
110. Bondong S, Kiefel H, Hielscher T, et al. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Ann. Oncol. 23(7), 1795-1802 (2012
111. Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Trope CG. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. Hum. Pathol. 44(11), 2449-2460 (2013
112. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol. Oncol. 133(2), 283-286 (2014
113. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front. Oncol. 4, 21 (2014
114. Moyer VA. US Preventive Services Task Force. Screening for ovarian cancer: US Preventive Services Task Force reaffirmation recommendation statement. Ann. Intern. Med. 157(12), 900-904 (2012
115. Slomski A. Screening women for ovarian cancer still does more harm than good. JAMA 307(23), 2474-2475 (2012
116. Partridge EE, Greenlee RT, Riley TL, et al. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet. Gynecol. 121(1), 25-31 (2013
117. Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-Analysis. Gynecol. Oncol. 130(3), 674-681 (2013
118. Gilbert L, Basso O, Sampalis J, Karp I, et al. DOvE Study Group. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 13(3), 285-291 (2012
119. Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19), 3454-3461 (2013
120. Morotti M, Becker CM, Menada MV, Ferrero S. Targeting tyrosine-kinases in ovarian cancer. Expert Opin. Investig. Drugs 22(10), 1265-1279 (2013
121. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol. Oncol. 131(2), 493-498 (2013
122. Davidson B, Tropé CG, Reich R. The role of the tumor stroma in ovarian cancer. Front Oncol. 4, 104 (2014